"Bonded by one chain, related to one purpose": what is primary in the development of thrombotic complications in COVID-19 — mechanisms of inflammation or endothelium damage?
- Authors: Cherkashin D.V.1
-
Affiliations:
- S.M. Kirov Military Medical Academy
- Issue: Vol 40, No 3 (2021)
- Pages: 45-49
- Section: Reviews
- URL: https://journal-vniispk.ru/RMMArep/article/view/76904
- DOI: https://doi.org/10.17816/rmmar76904
- ID: 76904
Cite item
Full Text
Abstract
The ongoing COVID-19 pandemic has caused significant morbidity and mortality worldwide, as well as a profound impact on society. Among the nosologies that increase the risk of a severe course of COVID-19, coronary heart disease, chronic heart failure, cardiomyopathy. The main complications caused by coronavirus infection include thrombotic ones. Spike protein SARS-CoV-2 can interact directly with platelets and fibrin, causing blood hypercoagulation and obstructing blood flow. The presence of the spike protein in circulation leads to structural changes in fibrin, complement 3 and prothrombin, which can contribute to hypercoagulability in COVID-19 positive patients and cause a significant violation of fibrinolysis. Endothelial damage and systemic inflammation, being interrelated triggers of coagulopathy characteristic of COVID-19, trigger a cascade of reactions resulting in thrombotic complications against the background of endothelial dysfunction and hyperinflammation, which may be of clinical importance in the treatment of hypercoagulability in patients with COVID-19 (bibliography: 14 refs).
Full Text
##article.viewOnOriginalSite##About the authors
Dmitriy V. Cherkashin
S.M. Kirov Military Medical Academy
Author for correspondence.
Email: cherkashin_dmitr@mail.ru
ORCID iD: 0000-0003-1363-6860
SPIN-code: 2781-9507
M.D., D.Sc. (Medicine), Professor
Russian Federation, 6, Akademika Lebedeva str., Saint Petersburg, 194044References
- Sergey Boytsov announced an increase in cases of late hospitalization for CVD by 25 %. Medvestnik. Available at: https://medvestnik.ru/content/news/Sergei-Boicov-zayavil-o-roste-sluchaev-pozdnei-gospitalizacii-po-povodu-SSZ-na-25.html (accessed 01.07.2021). (In Russ.)
- Kryukov EV, et al. Pathogenesis and clinical manifestations of cardiovascular lesions in patients with novel coronavirus infection (COVID-19). Saint Petersburg: S.M. Kirov Military Medical Academy Publishing House; 2021. 36 p. (In Russ.)
- Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489–500. doi: 10.1182/blood.2020006520
- Spiezia L, Boscolo A, Poletto F, et al. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thromb Haemost. 2020;120(6):998–1000. doi: 10.1055/s-0040-1710018
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3
- Eriksson O, Hultström M, Persson B, et al. Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients. Thromb Haemost. 2020;120(12):1720–1724. doi: 10.1055/s-0040-1715835
- Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation in patients with COVID-19: Anovel therapeutic target. J Allergy Clin Immunol. 2020;146(1):215–217. doi: 10.1016/j.jaci.2020.05.006
- Ip WK, Chan KH, Law HK, et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis. 2005;191(10):1697–1704. doi: 10.1086/429631
- Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019;18(9):707–729. doi: 10.1038/s41573-019-0031-6
- Liu W, Li H. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism. ChemRxiv. Predprint. 2020. doi: 10.26434/chemrxiv.11938173.v9
- Orlov YuP. Intravascular hemolysis of erythrocytes in the development of organ dysfunctions in critical conditions. Obshchaya reanimatologiya. 2008;6(2):88–94. (In Russ.) doi: 10.15360/1813-9779-2008-2-88
- Luzhnikov EA, ed. Medical toxicology. National guidelines. Moscow: GEOTAR-Media Publisher; 2014. 928 p. (In Russ.)
- Lodyagin AN, Batotsyrenov BV, Shikalova IA, Voznyuk IA. Acidosis and toxic hemolysis – goals of pathogenetic treatment of polyorgan pathology in COVID-19. Bulletin of Rehabilitation Medicine. 2020;97(3): 25–30. (In Russ.) doi: 10.38025/2078-1962-2020-97-3-25-30
- Grobbelaar LM, Venter C, Vlok M, et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19. medRxiv. Predprint. 2021. doi: 10.1101/2021.03.05.21252960
Supplementary files
